A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4083-4083
◽
Keyword(s):
Phase Ii
◽
2016 ◽
Vol 77
(2)
◽
pp. 243-250
◽